Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Opiant Pharmaceuticals Inc is a biotechnology business based in the US. Opiant Pharmaceuticals shares (OPNT) are listed on the NASDAQ and all prices are listed in US Dollars. Opiant Pharmaceuticals employs 30 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$25.29|
|52-week range||$6.79 - $28.61|
|50-day moving average||$22.89|
|200-day moving average||$16.00|
|Wall St. target price||$41.33|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.26|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-14)||1.93%|
|1 month (2021-09-21)||-1.94%|
|3 months (2021-07-21)||47.12%|
|6 months (2021-04-21)||138.36%|
|1 year (2020-10-21)||241.30%|
|2 years (2019-10-21)||63.27%|
|3 years (2018-10-19)||46.95%|
|5 years (2016-10-21)||208.41%|
Valuing Opiant Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Opiant Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Opiant Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $9.5 million.
The EBITDA is a measure of a Opiant Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$36.7 million|
|Gross profit TTM||$14.2 million|
|Return on assets TTM||-0.45%|
|Return on equity TTM||-3.17%|
|Market capitalisation||$100.7 million|
TTM: trailing 12 months
There are currently 22,508 Opiant Pharmaceuticals shares held short by investors – that's known as Opiant Pharmaceuticals's "short interest". This figure is 25.8% up from 17,888 last month.
There are a few different ways that this level of interest in shorting Opiant Pharmaceuticals shares can be evaluated.
Opiant Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Opiant Pharmaceuticals shares currently shorted divided by the average quantity of Opiant Pharmaceuticals shares traded daily (recently around 66200). Opiant Pharmaceuticals's SIR currently stands at 0.34. In other words for every 100,000 Opiant Pharmaceuticals shares traded daily on the market, roughly 340 shares are currently held short.
However Opiant Pharmaceuticals's short interest can also be evaluated against the total number of Opiant Pharmaceuticals shares, or, against the total number of tradable Opiant Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Opiant Pharmaceuticals's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Opiant Pharmaceuticals shares in existence, roughly 10 shares are currently held short) or 0.0055% of the tradable shares (for every 100,000 tradable Opiant Pharmaceuticals shares, roughly 6 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Opiant Pharmaceuticals.
Find out more about how you can short Opiant Pharmaceuticals stock.
We're not expecting Opiant Pharmaceuticals to pay a dividend over the next 12 months.
Opiant Pharmaceuticals's shares were split on a 1:100 basis on 30 December 2014. So if you had owned 100 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Opiant Pharmaceuticals shares – just the quantity. However, indirectly, the new 9900% higher share price could have impacted the market appetite for Opiant Pharmaceuticals shares which in turn could have impacted Opiant Pharmaceuticals's share price.
Over the last 12 months, Opiant Pharmaceuticals's shares have ranged in value from as little as $6.7878 up to $28.61. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Opiant Pharmaceuticals's is 0.5143. This would suggest that Opiant Pharmaceuticals's shares are less volatile than average (for this exchange).
Opiant Pharmaceuticals, Inc. , a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes medicines for the treatment for opioid overdose reversal; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.